Last reviewed · How we verify
NCT04766697
SAVA Syndemic Risk Reduction for African American Couples
NA trial testing Risk-Reduction Sessions in SAVA in 20 participants. Completed in 31 July 2021.
31 July 2021
Quick facts
| Lead sponsor | University of Maryland, College Park |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 20 |
| Start date | 1 March 2021 |
| Primary completion | 31 July 2021 |
| Estimated completion | 31 July 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Risk-Reduction Sessions
Conditions studied
- SAVA — all drugs for SAVA →
Sponsor
University of Maryland, College Park
Who can join
Adults 18 to 49, any sex, with SAVA. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Synergistic interactions among substance abuse, violence, and HIV/AIDS, dubbed the SAVA syndemic, are highly linked to HIV acquisition among African Americans. Given limited literature and development of interventions for HIV-negative but high-risk heterosexual AA couples, there is a need for SAVA risk-reduction development tailored to this population. Phase 1 consisted of qualitative interviews with 16 couples who met study criteria to gather input and information to adapt an 8-session couple-based SAVA syndemic informed risk reduction intervention for HIV-negative, AA heterosexual couples who reported intimate partner violence (IPV) and substance abuse. Phase 2 is the focus of this trial and will consist of delivery of the intervention to 20 couples who meet study inclusion criteria to test the adapted intervention. Given the disproportionate impact of HIV on AAs, this study addresses a key gap in literature by testing the first SAVA informed risk-reduction intervention for high-risk, HIV-negative, heterosexual AA couples.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04766697
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Maryland, College Park trials
Trials by the same sponsor.
- NCT07134543 — Using the Smart Underwear Device to Determine a Baseline of Flatus Activity Normalized to Fiber Intake · recruiting
- NCT07162376 — How Clinical and Personal Information Shape Physicians' Risk Judgments · NA · completed
- NCT06985641 — Khanya Ekhaya: A Home-Based Intervention · NA · not yet recruiting
- NCT06724705 — Testing the Capability of the Smart Underwear Device to Detect Increased Microbiome Activity Following Lactose Consumpti · NA · recruiting
- NCT06305039 — Optimizing Bilateral and Single-sided-deafness Cochlear Implants for Functioning in Complex Auditory Environments · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04766697 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Maryland, College Park
- Last refreshed: 30 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04766697.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing